 Data relating to demographics and baseline characteristics, and regarding efficacy and safety observations and parameters will be summarized, as will likewise be done for the main concomitant diseases recorded upon inclusion into the study. Listings will be created for patients who discontinue the study and will describe the reasons therefore. 